Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock Short Interest Report for October

by · The Markets Daily

Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report) saw a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 176,136 shares, a growth of 61.4% from the October 15th total of 109,110 shares. Based on an average trading volume of 255,474 shares, the short-interest ratio is presently 0.7 days. Currently, 1.1% of the shares of the stock are short sold.

Institutional Trading of Marker Therapeutics

An institutional investor recently bought a new stake in Marker Therapeutics stock. Concurrent Investment Advisors LLC acquired a new stake in Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned about 0.41% of Marker Therapeutics at the end of the most recent quarter. 22.39% of the stock is owned by institutional investors and hedge funds.

Marker Therapeutics Stock Performance

Shares of Marker Therapeutics stock traded down $0.04 on Monday, reaching $0.83. 135,857 shares of the company’s stock were exchanged, compared to its average volume of 199,889. Marker Therapeutics has a 52 week low of $0.82 and a 52 week high of $2.46. The firm’s 50-day moving average is $1.05 and its two-hundred day moving average is $1.32. The company has a market capitalization of $13.81 million, a P/E ratio of -2.02 and a beta of 1.65.

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $2.12 million. On average, analysts expect that Marker Therapeutics will post -0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MRKR. Weiss Ratings cut shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Zacks Research raised Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 15th. Finally, HC Wainwright restated a “buy” rating on shares of Marker Therapeutics in a research report on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Marker Therapeutics has an average rating of “Moderate Buy” and an average target price of $10.00.

Check Out Our Latest Report on MRKR

Marker Therapeutics Company Profile

(Get Free Report)

Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.

See Also